Real-life data have strongly suggested that an increased number of bacterial infections occurs in patients with cirrhosis receiving triple antiviral therapy with TVR or BOC, especially those with low platelets and low albumin levels [7–9]. This evidence concerns the gene ALB and bacterial infectious disease.